Table 3. Mean fractional reduction (±SD) in PCV according to treatment group (AQ+SP: amodiaquine+sulphadoxine-pyrimethamine; CD+A: chlorproguanil-dapsone+artesunate), G6PD status (deficient: hemizygous males and homozygous females) and proportion of patients whose PCV fell below 20 and 25%.
| Group | n | Fractional reduction (SD) | No. with PCV below 20% (%)b | No. with PCV below 25% (%) |
| CD+A G6PD (B) | 322 | 14.4 (7.9) | 7 (2.2) | 71 (22.0) |
| CD+A G6PD (A-) | 21 | 22.3 (11.8) | 4 (19.0) | 10 (47.6) |
| AQ+SP G6PD (B) | 342 | 16.4 (9.3) | 9 (2.6) | 93 (27.2) |
| AQ+SP G6PD (A-) | 17 | 15.1 (9.4) | 1 (5.9) | 4 (23.5) |
| p = 0.0001 | p = 0.005 | p = 0.05 |
b
Results by gender: CD+A G6PD (B) 5 girls and 2 boys; CD+A G6PD, 4 boys; AQ+SP G6PD (B) 1 girl and 8 boys; AQ+SP G6PD (A-) 1 girl.